Literature DB >> 1149303

Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.

S Lal, J B Martin, C E De la Vega, H G Friesen.   

Abstract

Apomorphine hydrochloride (0.75 mg s.c.) has been compared with L-dopa (500 mg p.o.) in their effects on growth hormone secretion in a double blind cross-over study involving nine healthy men. Apomorphine increased serum GH levels above 10 ng/ml in all nine subjects 30-60 min after injection. In contrast, only six of these subjects showed a similar elevation with L-DOPA and in only three had the level increased above 6 ng/ml by 60 min. One subject failed to respond to L-dopa and in two others the peak was less than 6 ng/ml. GH levels were significantly higher at 30, 45 and 60 min following apomorphine than following L-dopa. Apomorphine-induced GH release was not related to changes in serum cortisol or blood sugar. Benztropine mesylate (1 mg i.m.) had no effect on apomorphine-induced GH release. These results suggest: (a) apomorphine may have advantages over L-dopa as a provocative agent to assess GH secretory capacity; (b) a dopaminergic mechanism subserves GH secretion; (c) cholinergic mechanisms do not antagonize dopaminergic-related GH release.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1149303     DOI: 10.1111/j.1365-2265.1975.tb01535.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

2.  Parity-induced decrease in systemic growth hormone alters mammary gland signaling: a potential role in pregnancy protection from breast cancer.

Authors:  Robert K Dearth; David A Delgado; Jill K Hiney; Thushangi Pathiraja; Steffi Oesterreich; Dan Medina; W Les Dees; Adrian V Lee
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-09

3.  Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.

Authors:  J Rotrosen; B M Angrist; S Gershon; E J Sachar; F S Halpern
Journal:  Psychopharmacology (Berl)       Date:  1976-12-21       Impact factor: 4.530

4.  Hypothalamic-pituitary dopaminergic function in hepatic failure in man.

Authors:  S Lal; M Oravec; A Aronoff; M E Kiely; H Guyda; S Solomon; N P Nair
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

5.  Regulation of episodic growth hormone secretion by the central epinephrine system. Studies in the chronically cannulated rat.

Authors:  L C Terry; W R Crowley; M D Johnson
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

6.  Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.

Authors:  P Ettigi; N P Nair; S Lal; P Cervantes; H Guyda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-09       Impact factor: 10.154

7.  Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.

Authors:  F Müller-Spahn; M Ackenheil; M Albus; G May; D Naber; D Welter; K Zander
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Effect of choline on central dopaminergic function in normal subjects.

Authors:  S Lal; P Etienne; J Thavundayil; N P Nair; B Collier; R Rastogi; H Guyda; G Schwartz
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.